Медицинская литература. Новинки

 

 

 

 

 

 

Роль искусственного контрастирования при МРТ-диагностике рака предстательной железы (обзор литературы)

Вы можете загрузить полный текст статьи в формате pdf

Рассмотрены современные литературные данные о внедрении в клиническую практику высокоинформативных методов диагностики рака предстательной железы на основе явления магнитного резонанса: нативной Т1- и Т2-взвешенной томографии, динамической МРТ с контрастным усилением, диффузионных взвешенных изображений и МР-спектроскопии.

Ключевые слова:
рак предстательной железы, МРТ с контрастным усилением.

Литература:
1. Walsh P.C. Cambell’s urology, 8th ed. Philadelphia:
Saunders Company, 2002; 4: 2623–3952.
2. American Cancer Society. Cancer Facts and Figures
2008. Atlanta, GA: American Cancer Society, 2008. 1–84.
3. Давыдов М.И. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. Вестн. РОНЦ
им. Н.Н. Блохина РАМН 2006; 17 (3): 1–132.
4. Петров С.Б., Харченко П.В. Диагностика локализованного рака предстательной железы. Урология 2005; 1:
19–22.
5. Китаев С.В. Диагностические возможности магнитнорезонансной томографии с использованием катушки
для тела в определении стадии рака предстательной
железы. Онкоурология 2008; 4: 25–29.
6. Hricak H., White S., Vigneron D. et al. Cancer of the
prostate gland: MR imaging with pelvicphasedarray coils
versus integrated endorectalpelvic phased–array coils.
Radiology 1994; 193: 703–709.
7. White S., Hricak H., Forstner R. et al. Prostate cancer:
effect of postbiopsy hemorrhage on interpretation of MR
images. Radiology 1995; 195: 385–390.
8. Siegal J.A., Yu E., Brawer M.K. Topography of neovascularity in human prostate carcinoma. Cancer 1995; 75:
2545–2551.
9. Kozlowski P., Chang S.D., Jones E.C. et al. Combined diffusionweighted and dynamic contrastanhanced MRI for
prostate cancer diagnosiscorrelation with biopsy and
histopathology. J. Magn. Reson. Imaging 2006; 24:
108–113.
10. Fuchsjager M., Akin O., ShuklaDave A. et al. The role of
MRI and MRSI in diagnosis, treatment selection, and posttreatment followup for prostate cancer. Clin. Adv.
Hematol. Oncol. 2009; 7: 193–202.
11. Mullerad M., Hricak H., Kuroiwa K. et al. Comparison of
endorectal magnetic resonance imaging, guided prostate
biopsy and digital rectal examination in the preoperative
anatomical localization of prostate cancer. J. Urol. 2005:
174: 2158–2163.
12. Jager G.J., Ruijet E.T., van de Kaa C.A. et al. Local staging
of prostate cancer with endorectal MR imaging: correla
tion with histopathology. Am. J. Roentgenol. 1996; 166:
845–852.
13. Perrotti M., Kaufman R.P. Jr., Jennings T.A. et al. Endorectal coil magnetic resonans imaging in clinically localized prostate cancer: is it accurate? J. Urol. 1996; 156:
106–109.
14. Quinn S.F., Franzini D.A., Demlow T.A. et al. MRI of
prostate cancer with an endorectal surface coil technique:
correlation with whole mount specimens. Radiology 1994;
190: 323–327.
15. Franiel T., Hamm B., Hricak H. Dynamic contrastenhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur. Radiol. 2011;
21 (3): 616–626.
16. Труфанов Г.Е. Магнитнорезонансная спектроскопия:
Руководство для врачей; Под ред. Г.Е. Труфанова, Л.А.
Тютина. СПб.: ЭЛБИСПб., 2008.
17. Scheidler J., Hricak H., Vigneron D.B. et al. Prostate cancer: localization with threedimensional proton MR spectroscopic imaging – clinicopathologic study. Radiology
1999; 213: 473–480.
18. Kim J.K., Hong S.S., Choi Y.J. et al. Washin rate on the
basis of dynamic contrastenhanced MRI: usefulness for
prostate cancer detection and localization. J. Magn.
Reson. Imaging 2005; 22: 639–646.
19. Lee N., Newhouse J.H., Olsson C.A. et al. Which patients
with newly diagnosed prostate cancer need a computed
tomography scan of the abdomen and pelvis? An analysis
based on 588 patients. Urology 1999; 54 (3): 490–494.
20. May F., Treumann T., Dettmar P. et al. Limited value of
endorectal magnetic resonance imaging and transrectal
ultrasonography in the staging of clinically localized
prostate cancer. Br. J. Urol. Int. 2001; 87 (1): 66–69.
21. Tanimoto A., Nakashina J., Kohno H. et al. Prostate cancer screening: the clinical value of diffusionweighted
imaging and dynamic MR imaging in combination with
T2weighted imaging. J. Magn. Recon. Imaging 2007;
25: 146–152.
22. Carlani M. Combined morphological [1H]MR spectroscopic and contrastenhanced imaging of human prostate
cancer with a 3Tesla scanner: preliminary experience.
Radiol. Med. 2008; 113: 670–688.
23. Scheenen T.W., Klomp D.W., Roll S.A. et al. Fast acquisitionweighted threedimensional proton MR spectroscopic imaging of the human prostate. Magn. Reson. Med.
2004; 52: 80–88.
24. Zakian K.L., Eberhardt S., Hricak H. et al. Transition zone
prostate cancer: metabolic characteristics at 1H MR
spectroscopic imaginginitial results. Radiology 2003;
329: 241–247.
25. Mountford C. Magnetic resonance imaging and spectroscopy of the prostate. MAGMA 2008; 21: 369–370.
26. Brown G., Macvivar S., Ayton V. et al. The role of intravenous contrast enhancement in magnetic resonance
imaging of prostatic carcinoma. Clin. Radiol.1995; 50:
601–606.
27. Мищенко А.В., Дубицкий Д.Л., Москаленко Е.А. и др.
Возможности магнитнорезонансной спектроскопии в
диагностике аденокарциномы предстательной железы. Лучевая диагност. и тер. 2010; 4 (1): 62–67.
28. Castillo M., Smith J.K., Kwock L., Wilber K. Apparent diffusion coefficients in the evaluation of highgrade cerebral
gliomas. Am. J. Neuroradiol. 2001; 22: 60–64.
29. Eis M., Els T., HoehnBerlage M., Hossmann K.A.
Quantitative diffusion MR imaging of cerebral tumor and
edema. Acta Neurochir. Suppl. (Wien) 1994; 60: 344–346.
30. Eis M., Els T., HoehnBerlage M. High resolution quantitative relaxation and diffusion MRI of three different experimental tumors in rat. Magn. Reson. Med. 1995; 34:
835–844.
31. Tien R.D., Felsberg G.J., Friedman H. et al. MR imaging of
highgrade cerebral gliomas: value of diffusionweighted
echoplanar pulse sequences. Am. J. Roentgenol. 1994;
162: 671–677.
32. Chan I., Wells W. 3rd, Mulkern R.V. et al. Detection of
prostate cancer by integration of linescan diffusion, T2-mapping and T2weighted magnetic resonance imaging;
a multichannel statistical classifer. Med. Phys. 2003; 30:
2390–2398.
33. Gibbs P., Tozer D.J., Liney G.P., Turnbull L.W. Comparison
of quantitative T2 mapping and diffusionweighted imaging in the normal and pathologic prostate. Magn. Reson.
Med. 2001; 46: 1054–1058.
34. Hosseinzadeh K., Schwarz S.D. Endorectal diffusion
weighted imaging in prostate cancer to differentiate
malignant and benign peripheral zone tissue. J. Magn.
Reson. Imaging 2004; 20: 654–661.
35. Issa B. In vivo measurement of the apparent diffusion
coefficient in normal and malignant prostatic tissues using
echoplanar imaging. J. Magn. Reson. Imaging 2002; 16:
196–200.
36. Sato C., Naganawa S., Nakamura T. et al. Differentiation of
noncancerous tissue and cancer lesions by apparent difftusion coefficient values in transition and peripheral zones of
he prostate. J. Magn. Reson. Imaging 2005; 21: 258–262.
37. Shimofusa R., Fujimoto H., Akamata H. et al. Diffusion-weighted imaging of prostate cancer. J. Comput. Assist.
Tomogr. 2005; 29: 149–153.
38. Katahira K., Takahara T., Oda S. et al. Ultra-high-b-value
diffusionweighted MR imaging for the detection of
prostate cancer: evaluation in 201 cases with histopathological correlation. Radiology 2011; 21: 188–196.
39. Kingsley P.B., Monahan W.G. Selection of the optimum b
factor for diffusionweighted magnetic resonance imaging assessment of ischemic stroke. Magn. Reson. Med.
2004; 51: 996–1001.
40. Young J.C., Jeong K.K., Namkug K. Functional MR
Imaging of Prostate Cancer. RadioGraphics 2007; 27:
63–77.
41. Поляев Ю.А., Юдин А.Л., Шимановский Н.Л. Применение контрастных средств в лучевой диагностике. М.:
Калганов, 2010.
42. Ocak I., Bernardo M., Metzger G. et al. Dynamic contrastenhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am. J. Roentgenol. 2007; 189:
849.
43. Brawer M.K., Deering R.E., Brown M. et al. Predictors of
pathologic stage in prostatic carcinoma: the role of neovascularity. Cancer 1994; 73: 678–687.
44. Delorme S., Knopp M.V. Noninvasive vascular imaging:
assessing tumourtumor vascularity. Eur. Radiol. 1998; 8:
517–527.
45. Yamashita Y., Baba T., Baba Y. et al. Dynamic contrastenhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its
importance in predicting the outcome of radiation therapy.
Radiology 2000; 216: 803–809.
46. Brix G., Semmler W., Port R. et al. Pharmacokinetic parameters in CNS GdDTPA enhanced MRI. J. Comput.
Assist. Tomogr. 1991; 15: 621–628.
47. Buckley D.L., Roberts C., Parker G.J. et al. Prostate cancer: evaluation of vascular characteristics with dynamic
contrast enhanced T1weighted MR imaginginitial experience. Radiology 2004; 233: 709–715.
48. Hawighorst H., Knopp M.V., Debus J. et al.
Pharmacokinetic MRI for assessment of malignant glioma
response to stereotactic radiotherapy: initial results.
J. Magn. Reson. Imaging 1998; 8: 783–788.
49. Hoffmann U., Brix G., Knopp M.V. et al. Pharmacokinetic
mapping of the breast: a new method for dynamic MR-mammography. Magn. Reson. Med. 1995; 33: 506–514.
50. Port R.E., Knopp M.V., Hoffmann U. et al. Multi-compartment analysis of gadolinium chelate kinetics:
bloodtissue exchange in mammary tumors as monitored
by dynamic MR imaging. J. Magn. Reson. Imaging 1999;
10: 233–241.
51. Noworolski S.M., Vignerom D.B., Chen A.P. et al. Dynamic
contrast enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues.
Magn. Reson. Imaging 2008; 26: 1071–1080.
52. Futterer J.J., Engelbrecht M.R., Huisman H.J. et al.
Staging prostate cancer with dynamic contrast-enanced
endorectal MR imaging prior to radical prostatectomy:
experienced versus less experienced readers. Radiology
2005; 237: 541–549.
53. Futterer J.J., Heijmink S.W., Scheenen T.W. et al. Prostate
cancer localization with dynamic contrastenhanced MR
imaging and proton MR spectroscopic imaging. Radiology
2006; 241: 449–458.
54. Rouviere O., Hartman R.P., Lyonnet D. Prostate MR imaging at highfield strength: evolution or revolution? Eur.
Radiol. 2006; 16: 276–284.
55. Portalez D., Rollin G., Leandri P. et al. Prospective comparison of T2WMRI and dynamiccontrastenhanced
MRI, 3DMR spectroscopic imaging or diffusion-weighted
MRI in repeat TRUSguided biopsies. Eur. Radiol. 2010; 20
(12): 2781–2790.
56. Liney G.P., Turnbull L.W., Knowles A.J. In vivo magnetic
resonance spectroscopy and dynamic contrast enhanced
imaging of the prostate gland. NMR Biomed. 1999; 12:
39–44.
57. Rouviere O., Raudrant A., Ecochard R. et al. Characterization of timeenhancement curves of benign and
malignant prostate tissue at dynamic MRI. Eur. Radiol.
2003; 13: 931–942.
58. Turnbull L.W., Buckley D.L., Turnbull L.S. et al.
Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MRI and histopathology. J. Magn. Reson.
Imaging 1999; 9: 311–316.
59. Engelbrecht M.R., Huisman H.J., Laheij R.J. et al.
Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrastenhanced MR imaging. Radiology 2003; 229:
248–254
60. Padhani A.R., MacVicar A.D., Gapinski C.J. et al. Effects of
androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology
2001; 218: 365–374.
61. Ito H., Kamoi K., Yokoyama K. et al. Visualization of
prostate cancer using dynamic contrastenhanced MRI:
comparison with transrectal power Doppler ultrasound. Br.
J. Radiol. 2003; 76: 617–624.
62. Oyen R.H. Dynamic contrastenhanced MRI of the
prostate: is this the way to proceed for characterization of
prostate carcinoma? Eur. Radiol. 2003; 13: 921–924.
63. Cheikh A.B., Girouin N., Colombel M. et al. Evaluation of
T2weighted and dynamic contrastenhanced MRI in
localizing prostate cancer before repeat biopsy. Eur.
Radiol. 2009; 19: 770–778.
64. Girouin N., MegeLechevallier F., Tonina Senes A. et al.
Prostate dynamic contrastenhanced MRI with simple
visual diagnostic criteria: is it reasonable? Eur. Radiol.
2007; 17: 1498–1509.
65. Jackson A.S., Reinsberg S.A., Sohaib S.A. et al. Dynamic
contrastenhanced MRI for prostate cancer localization.
Br. J. Radiol. 2009; 82: 148–156.
66. Kirkham A.P., Emberton M., Allen C. How good is MRI at
detecting and characterizing cancer within the prostate?
Eur. Urol. 2006; 50: 1163–1174.
67. Villers A., Puech P., Mouton D. et al. Dynamic contrastenhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings.
J. Urol. 2006; 176: 2432–2437.
68. Sakai I., Harada K., Kurahashi T. et al. Usefulness of the
nadir value of serum prostatespecific antigen measured
by an ultrasensitive assay as a predictor of biochemical
recurrence after radical prostatectomy for clinically localized prostate cancer. Urol. Int. 2006; 76: 227–231
69. Casciani E., Polettini E., Carmenini E. et al. Endorectal and
dynamic contrastenhanced MRI for detection of local
recurrence after radical prostatectomy. Am. J. Roent
genol. 2008; 190: 1187–1192.
70. Cirillo S., Petracchini M., Scotti L. et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted
and contrastenhanced imaging. Eur. Radiol. 2009; 19:
761–769.
71. Biondetti P.R., Lee J.K., Ling D. et al. Clinical stage B
prostate carcinoma: staging with MR imaging. Radiolgy
1987; 162: 325–329.
72. Presti J.Jr., Hricak H., Narayan P.A. et al. Local staging of
prostatic carcinoma: comparison of transrectal sonogra
phy and endorectal MR imaging. Am. J. Roentgenol.
1996; 166: 103–108.
73. Tempany C.M., Zhou X., Zerhouni E.A. et al. Staging of
prostate cancer: results of Radiology Diagnostic Oncology
Group project comparison of three MR imaging techniques. Radiology 1994; 192: 47–54.
74. Ogura K., Maekawa S., Okubo K. et al. Dynamic endorectal magnetic resonance imaging for local staging and
detection of neurovascular bundle involvement of prostate
cancer: correlation with histopathologic results. Urology
2001; 57: 721–726.
75. Bloch B.N., FurmanHaran E., Helbich T.H. et al. Prostate
cancer: accurate determination of extracapsular extension with highspatialresolution dynamic contrastenhanced and T2weighted MR imaginginitial results.
Radiology 2007; 245: 176–185.
76. Ocak I., Bernardo M., Metzger G. et al. Dynamic contrastenhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am. J. Roentgenol. 2007; 189:
849.
77. Lemaitre L., Puech P., Poncelet E. et al. Dynamic contrastenhanced MRI of anterior prostate cancer: morphometric
assessment and correlation with radical prostatectomy
findings. Eur. Radiol. 2009; 19 (2): 470–480.

Contrast Enhancement in MRIDiagnostics of Prostate Cancer. Literature Review

It has been reviewed the modern literature data of current and potential future clinical applications of MR imaging techniques: MRI with contrast enhancement, diffusionweighted MRI, magnetic resonance spectroscopy for prostate cancer detection, localization, and staging

Keywords:
prostate cancer, MRI with contrast enhancement.